Amgen (AMGN) Stock Forecast, Price Target & Predictions
AMGN Stock Forecast
Amgen stock forecast is as follows: an average price target of $293.15 (represents a -7.50% downside from AMGN’s last price of $316.91) and a rating consensus of 'Buy', based on 24 wall street analysts offering a 1-year stock forecast.
AMGN Price Target
The average price target for Amgen (AMGN) is $293.15 based on 1-year price targets from 24 Wall Street analysts in the past 3 months, with a price target range of $380.00 to $182.00. This represents a potential -7.50% downside from AMGN's last price of $316.91.
AMGN Analyst Ratings
According to 24 Wall Street analysts, Amgen's rating consensus is 'Buy'. The analyst rating breakdown for AMGN stock is 0 'Strong Buy' (0.00%), 15 'Buy' (62.50%), 8 'Hold' (33.33%), 1 'Sell' (4.17%), and 0 'Strong Sell' (0.00%).
Amgen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Terence Flynn | Morgan Stanley | $319.00 | $316.74 | 0.71% | 0.66% |
| Oct 16, 2024 | Salveen Richter | Goldman Sachs | $369.00 | $325.09 | 13.51% | 16.44% |
| Oct 07, 2024 | Carter Gould | Barclays | $315.00 | $319.66 | -1.46% | -0.60% |
| Sep 25, 2024 | Evan David Seigerman | BMO Capital | $362.00 | $330.92 | 9.39% | 14.23% |
| Sep 25, 2024 | Christopher Raymond | Raymond James | $344.00 | $330.92 | 3.95% | 8.55% |
| Sep 25, 2024 | Brian Skorney | Robert W. Baird | $215.00 | $330.92 | -35.03% | -32.16% |
| Aug 07, 2024 | Mohit Bansal | Wells Fargo | $335.00 | $328.95 | 1.84% | 5.71% |
| Aug 06, 2024 | Terence Flynn | Morgan Stanley | $303.00 | $330.79 | -8.40% | -4.39% |
| Jun 14, 2024 | Gregory Renza | RBC Capital | $332.00 | $298.71 | 11.14% | 4.76% |
| May 17, 2024 | Jay Olson | Oppenheimer | $380.00 | $312.32 | 21.67% | 19.91% |
The latest Amgen stock forecast, released on Oct 21, 2024 by Terence Flynn from Morgan Stanley, set a price target of $319.00, which represents a 0.71% increase from the stock price at the time of the forecast ($316.74), and a 0.66% increase from AMGN last price ($316.91).
Amgen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 8 | 16 |
| Avg Price Target | $334.33 | $320.25 | $318.81 |
| Last Closing Price | $316.91 | $316.91 | $316.91 |
| Upside/Downside | 5.50% | 1.05% | 0.60% |
In the current month, the average price target of Amgen stock is $334.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 5.50% increase as opposed to Amgen's last price of $316.91. This month's average price target is up 4.40% compared to last quarter, and up 4.87% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 21, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 17, 2024 | Bernstein | - | Outperform | Initialise |
| Oct 16, 2024 | Goldman Sachs | Conviction Buy | Conviction Buy | Hold |
| Oct 07, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Sep 27, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Sep 25, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 25, 2024 | BMO Capital | Outperform | Outperform | Hold |
Amgen's last stock rating was published by Wells Fargo on Oct 22, 2024. The company gave AMGN a "Buy" rating, the same as its previous rate.
Amgen Financial Forecast
Amgen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $8.20B | $6.90B | $6.99B | $6.11B | $6.84B | $6.65B | $6.59B | $6.24B | $6.85B | $6.71B | $6.53B | $5.90B | $6.63B | $6.42B | $6.21B | $6.16B | $6.20B | $5.74B |
| Avg Forecast | $8.70B | $8.47B | $8.47B | $7.91B | $8.87B | $8.64B | $8.69B | $8.14B | $8.85B | $8.50B | $8.35B | $7.45B | $8.13B | $6.93B | $6.66B | $6.15B | $6.74B | $6.56B | $6.53B | $6.07B | $6.87B | $6.67B | $6.46B | $6.26B | $6.57B | $6.39B | $6.19B | $6.00B | $6.03B | $5.63B |
| High Forecast | $9.03B | $8.79B | $8.80B | $8.21B | $9.22B | $8.97B | $9.02B | $8.46B | $9.11B | $8.50B | $8.35B | $7.45B | $8.30B | $8.33B | $6.92B | $6.39B | $7.00B | $6.56B | $6.53B | $6.07B | $6.87B | $6.67B | $6.46B | $6.26B | $6.57B | $6.39B | $6.19B | $6.00B | $6.03B | $5.63B |
| Low Forecast | $8.25B | $8.02B | $8.03B | $7.49B | $8.41B | $8.19B | $8.24B | $7.68B | $8.54B | $8.50B | $8.35B | $7.45B | $7.98B | $6.73B | $6.32B | $5.83B | $6.39B | $6.56B | $6.53B | $6.07B | $6.87B | $6.67B | $6.46B | $6.26B | $6.57B | $6.39B | $6.19B | $6.00B | $6.03B | $5.63B |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 15 | 7 | 9 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.05% | 0.99% | 1.01% | 1.01% | 1.01% | 1.03% | 1.00% | 1.01% | 1.01% | 0.94% | 1.01% | 1.01% | 1.00% | 1.03% | 1.03% | 1.02% |
Amgen's average Quarter revenue forecast for Mar 24 based on 9 analysts is $7.45B, with a low forecast of $7.45B, and a high forecast of $7.45B. AMGN's average Quarter revenue forecast represents a -9.08% decrease compared to the company's last Quarter revenue of $8.20B (Dec 23).
Amgen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 15 | 7 | 9 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.27B | $2.02B | $2.68B | $3.98B | $2.16B | $2.76B | $1.86B | $1.97B | $3.32B | $3.30B | $3.20B | $2.98B | $3.07B | $3.41B | $3.26B | $3.26B | $2.99B | $3.10B |
| Avg Forecast | $3.54B | $3.45B | $3.45B | $3.22B | $3.61B | $3.52B | $3.54B | $3.32B | $3.60B | $3.46B | $3.40B | $3.28B | $3.31B | $2.82B | $2.71B | $2.98B | $3.46B | $2.67B | $2.66B | $2.71B | $2.80B | $2.71B | $2.63B | $3.24B | $2.68B | $2.60B | $2.52B | $2.91B | $2.45B | $2.29B |
| High Forecast | $3.68B | $3.58B | $3.58B | $3.34B | $3.75B | $3.65B | $3.67B | $3.45B | $3.71B | $3.46B | $3.40B | $3.93B | $3.38B | $3.39B | $2.82B | $3.57B | $4.15B | $2.67B | $2.66B | $3.25B | $2.80B | $2.71B | $2.63B | $3.89B | $2.68B | $2.60B | $2.52B | $3.49B | $2.45B | $2.29B |
| Low Forecast | $3.36B | $3.27B | $3.27B | $3.05B | $3.42B | $3.33B | $3.35B | $3.13B | $3.48B | $3.46B | $3.40B | $2.62B | $3.25B | $2.74B | $2.57B | $2.38B | $2.76B | $2.67B | $2.66B | $2.17B | $2.80B | $2.71B | $2.63B | $2.59B | $2.68B | $2.60B | $2.52B | $2.33B | $2.45B | $2.29B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.72% | 0.99% | 1.34% | 0.63% | 1.03% | 0.70% | 0.73% | 1.19% | 1.22% | 1.22% | 0.92% | 1.15% | 1.31% | 1.29% | 1.12% | 1.22% | 1.35% |
9 analysts predict AMGN's average Quarter EBITDA for Mar 24 to be $3.28B, with a high of $3.93B and a low of $2.62B. This is 157.82% upper than Amgen's previous annual EBITDA (Dec 23) of $1.27B.
Amgen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 15 | 7 | 9 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $767.00M | $1.73B | $1.38B | $2.84B | $1.62B | $2.14B | $1.32B | $1.48B | $1.90B | $1.88B | $464.00M | $1.65B | $1.61B | $2.02B | $1.80B | $1.82B | $1.70B | $1.97B |
| Avg Forecast | $2.15B | $3.07B | $2.87B | $2.63B | $2.87B | $2.93B | $2.91B | $2.54B | $2.76B | $2.86B | $2.70B | $1.72B | $2.49B | $2.53B | $2.44B | $1.56B | $1.98B | $2.42B | $2.40B | $1.42B | $2.18B | $2.32B | $2.21B | $1.79B | $1.82B | $2.12B | $2.07B | $1.63B | $1.84B | $1.91B |
| High Forecast | $2.26B | $3.23B | $3.01B | $2.77B | $3.02B | $3.08B | $3.06B | $2.77B | $3.33B | $2.90B | $2.70B | $2.06B | $2.72B | $2.67B | $2.56B | $1.88B | $2.37B | $2.42B | $2.40B | $1.71B | $2.18B | $2.32B | $2.21B | $2.15B | $1.82B | $2.12B | $2.07B | $1.95B | $1.84B | $1.91B |
| Low Forecast | $2.01B | $2.87B | $2.67B | $2.46B | $2.68B | $2.73B | $2.71B | $2.24B | $-1.48B | $2.82B | $2.70B | $1.38B | $2.32B | $2.32B | $2.27B | $1.25B | $1.58B | $2.42B | $2.40B | $1.14B | $2.18B | $2.32B | $2.21B | $1.43B | $1.82B | $2.12B | $2.07B | $1.30B | $1.84B | $1.91B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.31% | 0.68% | 0.57% | 1.82% | 0.82% | 0.89% | 0.55% | 1.04% | 0.87% | 0.81% | 0.21% | 0.92% | 0.89% | 0.95% | 0.87% | 1.12% | 0.92% | 1.03% |
Amgen's average Quarter net income forecast for Mar 24 is $1.72B, with a range of $1.38B to $2.06B. AMGN's average Quarter net income forecast represents a 124.33% increase compared to the company's last Quarter net income of $767.00M (Dec 23).
Amgen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 15 | 7 | 9 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $2.27B | $1.35B | $1.29B | $1.26B | $1.57B | $1.29B | $1.33B | $1.23B | $1.43B | $1.30B | $1.38B | $1.25B | $1.77B | $1.35B | $1.29B | $1.32B | $1.51B | $1.22B |
| Avg Forecast | $1.87B | $1.82B | $1.83B | $1.70B | $1.91B | $1.86B | $1.87B | $1.75B | $1.91B | $1.83B | $1.80B | $1.43B | $1.75B | $1.49B | $1.44B | $1.30B | $1.48B | $1.41B | $1.41B | $1.18B | $1.48B | $1.44B | $1.39B | $1.36B | $1.42B | $1.38B | $1.33B | $1.17B | $1.30B | $1.21B |
| High Forecast | $1.95B | $1.89B | $1.90B | $1.77B | $1.99B | $1.93B | $1.94B | $1.82B | $1.96B | $1.83B | $1.80B | $1.72B | $1.79B | $1.79B | $1.49B | $1.56B | $1.78B | $1.41B | $1.41B | $1.42B | $1.48B | $1.44B | $1.39B | $1.63B | $1.42B | $1.38B | $1.33B | $1.41B | $1.30B | $1.21B |
| Low Forecast | $1.78B | $1.73B | $1.73B | $1.61B | $1.81B | $1.76B | $1.77B | $1.65B | $1.84B | $1.83B | $1.80B | $1.15B | $1.72B | $1.45B | $1.36B | $1.04B | $1.19B | $1.41B | $1.41B | $946.46M | $1.48B | $1.44B | $1.39B | $1.09B | $1.42B | $1.38B | $1.33B | $938.00M | $1.30B | $1.21B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% | 0.91% | 0.90% | 0.97% | 1.06% | 0.91% | 0.94% | 1.04% | 0.96% | 0.91% | 0.99% | 0.92% | 1.25% | 0.98% | 0.97% | 1.12% | 1.16% | 1.01% |
Amgen's average Quarter SG&A projection for Mar 24 is $1.43B, based on 9 Wall Street analysts, with a range of $1.15B to $1.72B. The forecast indicates a -37.05% fall compared to AMGN last annual SG&A of $2.27B (Dec 23).
Amgen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 15 | 7 | 9 | 9 | 10 | 18 | 15 | 9 | 10 | 16 | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.43 | $3.23 | $2.58 | $5.32 | $3.02 | $4.01 | $2.46 | $2.69 | $3.38 | $3.32 | $0.81 | $2.85 | $2.78 | $3.45 | $3.07 | $3.09 | $2.87 | $3.29 |
| Avg Forecast | $3.97 | $5.67 | $5.29 | $4.86 | $5.30 | $5.41 | $5.37 | $4.70 | $5.10 | $5.27 | $4.98 | $3.88 | $4.59 | $4.67 | $4.49 | $3.85 | $4.10 | $4.47 | $4.43 | $4.10 | $4.04 | $4.29 | $4.09 | $4.05 | $3.36 | $3.93 | $3.82 | $3.74 | $3.41 | $3.53 |
| High Forecast | $4.17 | $5.96 | $5.56 | $5.10 | $5.57 | $5.67 | $5.64 | $5.12 | $6.15 | $5.35 | $4.99 | $3.88 | $5.02 | $4.92 | $4.72 | $4.04 | $4.30 | $4.47 | $4.43 | $4.10 | $4.04 | $4.29 | $4.09 | $4.05 | $3.36 | $3.93 | $3.82 | $3.74 | $3.41 | $3.53 |
| Low Forecast | $3.70 | $5.29 | $4.93 | $4.53 | $4.94 | $5.04 | $5.00 | $4.13 | $-2.73 | $5.20 | $4.98 | $3.88 | $4.29 | $4.29 | $4.19 | $3.59 | $3.82 | $4.47 | $4.43 | $4.10 | $4.04 | $4.29 | $4.09 | $4.05 | $3.36 | $3.93 | $3.82 | $3.74 | $3.41 | $3.53 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.31% | 0.69% | 0.57% | 1.38% | 0.74% | 0.90% | 0.55% | 0.66% | 0.84% | 0.77% | 0.20% | 0.70% | 0.83% | 0.88% | 0.80% | 0.83% | 0.84% | 0.93% |
According to 9 Wall Street analysts, Amgen's projected average Quarter EPS for Mar 24 is $3.88, with a low estimate of $3.88 and a high estimate of $3.88. This represents a 171.26% increase compared to AMGN previous annual EPS of $1.43 (Dec 23).
Amgen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
| BIIB | Biogen | $173.52 | $276.38 | 59.28% | Buy |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| LLY | Eli Lilly and Company | $806.14 | $782.65 | -2.91% | Buy |
| AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
AMGN Forecast FAQ
Is Amgen a good buy?
Yes, according to 24 Wall Street analysts, Amgen (AMGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 62.50% of AMGN's total ratings.
What is AMGN's price target?
Amgen (AMGN) average price target is $293.15 with a range of $182 to $380, implying a -7.50% from its last price of $316.91. The data is based on 24 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amgen stock go up soon?
According to Wall Street analysts' prediction for AMGN stock, the company can go down by -7.50% (from the last price of $316.91 to the average price target of $293.15), up by 19.91% based on the highest stock price target, and down by -42.57% based on the lowest stock price target.
Can Amgen stock reach $500?
AMGN's average twelve months analyst stock price target of $293.15 does not support the claim that Amgen can reach $500 in the near future.
What is Amgen's current price target trend?
3 Wall Street analysts forecast a $334.33 price target for Amgen (AMGN) this month, up 5.50% from its last price of $316.91. Compared to the last 3 and 12 months, the average price target increased by 1.05% and increased by 0.60%, respectively.
What are Amgen's analysts' financial forecasts?
Amgen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.35B (high $35.67B, low $32.51B), average EBITDA is $13.98B (high $14.52B, low $13.24B), average net income is $11.26B (high $11.92B, low $10.36B), average SG&A $7.4B (high $7.69B, low $7.01B), and average EPS is $20.77 (high $21.99, low $19.12). AMGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $33.55B (high $34.83B, low $31.8B), average EBITDA is $13.66B (high $14.18B, low $12.94B), average net income is $10.73B (high $11.27B, low $10B), average SG&A $7.23B (high $7.51B, low $6.85B), and average EPS is $19.8 (high $20.79, low $18.46).
Did the AMGN's actual financial results beat the analysts' financial forecasts?
Based on Amgen's last annual report (Dec 2023), the company's revenue was $28.19B, beating the average analysts forecast of $27.87B by 1.15%. Apple's EBITDA was $7.9B, missing the average prediction of $11.82B by -33.18%. The company's net income was $6.72B, missing the average estimation of $9.02B by -25.52%. Apple's SG&A was $6.18B, beating the average forecast of $5.98B by 3.32%. Lastly, the company's EPS was $12.56, missing the average prediction of $17.6 by -28.64%. In terms of the last quarterly report (Dec 2023), Amgen's revenue was $8.2B, beating the average analysts' forecast of $8.13B by 0.86%. The company's EBITDA was $1.27B, missing the average prediction of $3.31B by -61.58%. Amgen's net income was $767M, missing the average estimation of $2.49B by -69.18%. The company's SG&A was $2.27B, beating the average forecast of $1.75B by 29.88%. Lastly, the company's EPS was $1.43, missing the average prediction of $4.59 by -68.85%